• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Remicade does well in study on inflammation

Article

Washington, D.C. - In a recent 10-week, three-dose phase II trial of inflaximab (Remicade), 87.9 percent of the 250 participants achieved PASI 75, while 58 percent achieved PASI 90 at the 10-week mark.

Related Videos
Related Content
Federal Trade Commission Votes to Ban Noncompete Clauses Between Employers and Workers

Federal Trade Commission Votes to Ban Noncompete Clauses Between Employers and Workers

Article
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast
US Central and European Commands Should Revisit Disallowance of Systemic Treatments for Deployed Individuals With Psoriasis, Eczema, Paper Argues

US Central and European Commands Should Revisit Disallowance of Systemic Treatments for Deployed Individuals With Psoriasis, Eczema, Paper Argues

Article
ReV Up Your Vitiligo Treatment Strategies

ReV Up Your Vitiligo Treatment Strategies

Podcast
ASLAN Announces Positive Phase 2 Results of Eblasakimab in Dupilumab-Treated Patients With AD

ASLAN Announces Positive Phase 2 Results of Eblasakimab in Dupilumab-Treated Patients With AD

Article
Jessner’s Lymphocytic Infiltration of the Skin Mimicking Rosacea: A Rare Case Presentation

Jessner’s Lymphocytic Infiltration of the Skin Mimicking Rosacea: A Rare Case Presentation

Article
© 2024 MJH Life Sciences

All rights reserved.